These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 16236753)

  • 21. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
    Strüßmann T; Fritsch K; Baumgarten A; Fietz T; Engelhardt M; Mertelsmann R; Ihorst G; Duyster J; Finke J; Marks R
    Br J Haematol; 2017 Sep; 178(6):927-935. PubMed ID: 28643323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
    Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
    Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis.
    Martelli MP; Martelli M; Pescarmona E; De Sanctis V; Donato V; Palombi F; Todisco E; Rendina EA; Pau FM; Mandelli F
    Ann Oncol; 1998 Sep; 9(9):1027-9. PubMed ID: 9818079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency.
    Ramadan KM; Shenkier T; Sehn LH; Gascoyne RD; Connors JM
    Ann Oncol; 2007 Jan; 18(1):129-135. PubMed ID: 17018705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of different chemotherapy programs, indications for surgery and radiotherapy in primary mediastinal B-cell lymphosarcoma].
    Dzhumabaeva BT; Kremenetskaia AM; Gotman LN; Shavlokhov VS; Kaplanskaia IB; Kravchenko SK; Vishnevskaia ES; Gemdzhian EG; Frank GA
    Ter Arkh; 2005; 77(8):78-81. PubMed ID: 16206611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.
    Villa D; Connors JM; Shenkier TN; Gascoyne RD; Sehn LH; Savage KJ
    Ann Oncol; 2010 May; 21(5):1046-52. PubMed ID: 19861575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
    Kumar A; Lunning MA; Zhang Z; Migliacci JC; Moskowitz CH; Zelenetz AD
    Br J Haematol; 2015 Dec; 171(5):776-83. PubMed ID: 26456939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary mediastinal large B-cell lymphoma: the need for prospective controlled clinical trials.
    Bieri S; Roggero E; Zucca E; Bertoni F; Pianca S; Sanna P; Pedrinis E; Bernier J; Cavalli F
    Leuk Lymphoma; 1999 Nov; 35(5-6):537-44. PubMed ID: 10609791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.
    Vassilakopoulos TP; Papageorgiou SG; Angelopoulou MK; Chatziioannou S; Prassopoulos V; Karakatsanis S; Arapaki M; Mellios Z; Sachanas S; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Hatzimichael E; Kotsopoulou M; Dimou M; Variamis E; Boutsis D; Terpos E; Michali E; Karianakis G; Tsirkinidis P; Vadikolia C; Poziopoulos C; Pigaditou A; Vrakidou E; Siakantaris MP; Kyrtsonis MC; Symeonidis A; Anargyrou K; Papaioannou M; Chatziharissi E; Vervessou E; Tsirogianni M; Palassopoulou M; Gainaru G; Mainta C; Tsirigotis P; Assimakopoulou T; Konstantinidou P; Papadaki H; Dimopoulos MA; Pappa V; Karmiris T; Roussou P; Datseris I; Panayiotidis P; Konstantopoulos K; Pangalis GA; Rondogianni P
    Ann Hematol; 2021 Sep; 100(9):2279-2292. PubMed ID: 33523289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
    Kwon J; Kim IH; Kim BH; Kim TM; Heo DS
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):91-8. PubMed ID: 25721091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.
    Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M
    Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.
    Zhou H; Xu-Monette ZY; Xiao L; Strati P; Hagemeister FB; He Y; Chen H; Li Y; Manyam GC; Li Y; Montes-Moreno S; Piris MA; Young KH
    Blood Cancer J; 2020 May; 10(5):49. PubMed ID: 32366834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors.
    De Sanctis V; Alfò M; Di Rocco A; Ansuinelli M; Russo E; Osti MF; Valeriani M; Minniti G; Grapulin L; Musio D; Bracci S; Spagnoli A; Moleti ML; Tombolini V; Martelli M
    Hematol Oncol; 2017 Dec; 35(4):554-560. PubMed ID: 28078727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach.
    Hayden AR; Tonseth P; Lee DG; Villa D; Gerrie AS; Scott DW; Freeman CL; Slack GW; Farinha P; Skinnider B; Yenson PR; Benard F; Lo A; Pickles T; Wilson D; Connors JM; Sehn LH; Savage KJ
    Blood; 2020 Dec; 136(24):2803-2811. PubMed ID: 32603413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of primary mediastinal large B-cell lymphomas].
    Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
    Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.